Bovine Mastitis Market Size & Growth Forecast 2026–2035, By Segments (Product, Type, Therapy, Route of Administration, End-use), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Bovine Mastitis Market size stood at USD 1.77 Billion in 2025 and is predicted to grow at a 8.3% CAGR from 2026 to 2035, attaining USD 3.93 Billion by 2035. The industry revenue for 2026 is assessed at USD 1.9 billion.

• Base Year Value (2025): USD 1.77 Billion
• CAGR (2026-2035): 8.3%
• Forecast Year Value (2035): USD 3.93 Billion
• Historical Data Period: 2022-2025
• Largest Region: North America
• Forecast Period: 2026-2035

Bovine Mastitis Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America holds 40.00% share, supported by large commercial dairy herds, established veterinary networks, and routine on-farm diagnostics and treatment practices.
  • Asia Pacific grows at 9.38% CAGR due to dairy modernization, rising productivity focus, and expanding adoption of structured herd health and mastitis control systems.

• Segment Momentum:

  • Pharmaceuticals held a 61.95% share in 2025 because they remain the primary treatment for active mastitis infections, with antibiotics and supportive therapies routinely used in veterinary practice and farm treatment protocols.
  • Vaccines are growing fastest as dairy producers increasingly adopt preventive herd health strategies to reduce recurring infections, strengthen udder health management, and lessen reliance on repeated pharmaceutical treatments.

• Market Expansion Drivers:

  • Rising global dairy consumption increasing demand for effective udder infection management solutions.
  • Advancements in molecular diagnostics improving early detection and treatment accuracy for mastitis.
  • Growing awareness of subclinical mastitis driving preventive veterinary healthcare adoption.

• Leading Market Participants:

  Major players in the bovine mastitis market include Zoetis Inc. (United States), Boehringer Ingelheim International GmbH (Germany), Elanco Animal Health Incorporated (United States), Merck & Co., Inc. (United States), Ceva Santé Animale S.A. (France), HIPRA, S.A. (Spain), Virbac S.A. (France), ImmuCell Corporation (United States), Forte Healthcare Limited (New Zealand), Dechra Pharmaceuticals PLC (United Kingdom).

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2025 Market Size: USD 1.77 Billion
  • Projected Market Size: USD 3.93 Billion by 2035
  • Growth Forecasts: 8.3% CAGR (2026-2035)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: Pharmaceuticals (Product) | Clinical Mastitis (Type) | Dry Period (Therapy) | Intra-Mammary (Route of Administration) | Veterinary Hospitals/Clinics (End-use)
  • Emerging Opportunity Segment: Vaccines (Product) | Sub-Clinical Mastitis (Type) | Lactating Period (Therapy) | Intra-Mammary (Route of Administration) | Veterinary Hospitals/Clinics (End-use)

Market Growth Drivers and Industry Trends

Rising global dairy consumption increasing demand for effective udder infection management solutions

As dairy intake rises, producers face stronger pressure to maintain consistent milk output, herd productivity, and raw milk quality, which directly increases spending on prevention and treatment tools in the bovine mastitis market. Mastitis reduces yield, alters milk composition, and can trigger milk discard during treatment periods, so higher-value dairy production systems tend to adopt faster intervention protocols, routine udder health monitoring, and more reliable therapeutic products to protect farm economics. This dynamic is encouraging market growth for antibiotics, teat sealants, disinfectants, and herd health management services as commercial dairies become less willing to absorb losses linked to avoidable udder infections.

Advancements in molecular diagnostics improving early detection and treatment accuracy for mastitis

Improved molecular testing is reshaping clinical decision-making in the bovine mastitis market by allowing veterinarians and dairy operators to identify causative pathogens earlier and with greater precision than conventional methods. That practical shift matters because treatment choice, isolation decisions, and culling strategies depend heavily on whether infections are contagious, environmental, acute, or persistent. As more accurate diagnostics reduce empirical treatment and shorten the time between symptom recognition and targeted intervention, they are influencing market adoption of premium testing platforms alongside pathogen-specific therapeutics and integrated herd health programs.

Growing awareness of subclinical mastitis driving preventive veterinary healthcare adoption

Greater recognition of subclinical mastitis is changing purchasing behavior in the bovine mastitis market because producers are paying closer attention to infections that do not show obvious visual symptoms but still depress milk yield, elevate somatic cell counts, and weaken herd performance over time. This has moved herd health management away from a purely reactive model toward routine screening, dry cow therapy planning, teat hygiene protocols, and regular veterinary oversight. The result is reinforcing market demand for preventive products and monitoring solutions, especially where dairy operations are under pressure to improve milk quality standards and reduce long-term productivity losses.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Rising global dairy consumption increasing demand for effective udder infection management solutions	1.90%	Moderate	Asia Pacific, North America	High	Near Term
Advancements in molecular diagnostics improving early detection and treatment accuracy for mastitis	1.70%	High	North America, Europe	Medium	Mid Term
Growing awareness of subclinical mastitis driving preventive veterinary healthcare adoption	1.40%	Moderate	Asia Pacific, Latin America	Emerging	Mid Term

Regional Demand Dynamics

North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

North America held a 40.00% share of the bovine mastitis market in 2025, bolstered by the region’s large commercial dairy herd base, established veterinary care networks, and routine use of diagnostic and treatment protocols on farms. Market activity is reinforced by the practical need to limit milk yield losses, protect herd health, and manage the quality impact of mastitis within intensive dairy operations. The region’s leadership is also sustained by broader access to animal health products and stronger on-farm disease monitoring, which supports consistent adoption of mastitis management solutions across both prevention and treatment settings.

Asia Pacific is projected to expand at a 9.38% CAGR over the forecast period in the bovine mastitis market, driven by the ongoing modernization of dairy farming and rising attention to productivity losses linked to udder infections. Growth is accelerating as more producers shift from small-scale, low-intervention practices toward structured herd health management, increasing the use of veterinary services, farm hygiene measures, and disease detection approaches. As dairy output expectations rise across the region, adoption is moving beyond basic treatment toward more systematic mastitis control in day-to-day farm operations.

Regional Market Attractiveness & Strategic Fit Matrix
Parameter	North America	Asia Pacific	Europe	Latin America	MEA
Innovation Hub	Advanced	Developing	Advanced	Nascent	Nascent
Cost-Sensitive Region	Low	Medium	Low	High	High
Regulatory Environment	Supportive	Neutral	Restrictive	Neutral	Neutral
Demand Drivers	Moderate	Moderate	Moderate	Weak	Weak
Development Stage	Developed	Developing	Developed	Emerging	Emerging
Adoption Rate	Medium	Medium	Medium	Low	Low
New Entrants / Startups	Moderate	Moderate	Moderate	Sparse	Sparse
Macro Indicators	Strong	Stable	Stable	Weak	Weak

Key Country Insights

United States

Precision Herd Health

The U.S. bovine mastitis market centers on preventive herd health management supported by advanced diagnostics and data-driven dairy monitoring. Dairy producers in the U.S. increasingly adopt integrated disease management strategies that improve milk quality and treatment efficiency.

Japan

Dairy Quality Assurance

Japan prioritizes early mastitis detection and consistent herd health management to support high-quality dairy production. Producers in Japan increasingly adopt diagnostic technologies that enable timely intervention while reducing production losses associated with udder infections.

South Korea

Modern Livestock Care

South Korea is expanding veterinary management practices supported by improved dairy health monitoring and disease detection tools. Dairy farms in South Korea continue investing in practical mastitis management solutions that enhance animal welfare and operational consistency.

Germany

Preventive Dairy Management

Germany emphasizes preventive mastitis control through veterinary oversight, herd monitoring, and responsible therapeutic practices. Dairy operations in Germany continue strengthening disease surveillance to maintain animal health and support consistent milk production standards.

France

Herd Monitoring Strategies

France focuses on comprehensive udder health management through routine screening, veterinary guidance, and preventive farm practices. Dairy producers in France are integrating monitoring technologies with herd management programs to improve treatment planning and milk quality outcomes.

Italy

Veterinary Treatment Optimization

Italy strengthens bovine mastitis management through improved diagnostics, targeted treatment protocols, and preventive herd care. Dairy producers in Italy continue refining veterinary decision-making to support healthier livestock and more efficient dairy operations.

Segment Leadership and Growth Trends

  Product Segment Analysis: Pharmaceuticals (Largest Segment) vs Vaccines (Fastest-Growing Segment)

Pharmaceuticals held a 61.95% share of the bovine mastitis market in 2025, reflecting their established role as the primary treatment option once infection is identified in dairy herds. This leadership is underpinned by the routine and immediate need to manage active mastitis cases, where antibiotics and supportive drug therapies remain embedded in farm treatment protocols and veterinary practice. The pharmaceuticals segment also benefits from direct applicability across a wide range of infection severities, making it the most consistently used product category in the bovine mastitis market.

Vaccines are emerging as the fastest-growing segment in the bovine mastitis market because herd management is increasingly influenced by the need to reduce disease incidence before treatment becomes necessary. Their momentum is tied to the practical shift toward preventive health strategies, especially where farmers seek to limit recurring infections and reduce dependence on repeated pharmaceutical intervention. Compared with treatment-led alternatives, vaccines are seeing wider adoption through their fit with longer-term disease control programs and more structured udder health management approaches.

Type Segment Analysis: Clinical Mastitis (Largest Segment) vs Sub-Clinical Mastitis (Fastest-Growing Segment)

Within the bovine mastitis market, Clinical Mastitis accounted for the largest share in 2025 because it presents with visible symptoms that require immediate attention and direct intervention. Its leading position is backed by the clear economic and operational impact of symptomatic cases, which prompt faster diagnosis, treatment decisions, and veterinary involvement. Since clinical infections are more readily detected at the farm level, they continue to drive a substantial portion of product demand across the bovine mastitis market.

Sub-Clinical Mastitis is the fastest-growing segment in the bovine mastitis market as producers place greater emphasis on infections that are less visible but still affect milk quality and herd productivity. Growth in this segment is being backed by increased attention to early detection and ongoing monitoring, which brings previously underrecognized cases into formal management pathways. Relative to Clinical Mastitis, the momentum behind Sub-Clinical Mastitis comes from its closer connection to preventive herd health practices and the need to address production losses before they escalate into overt disease.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Product	Pharmaceuticals, Antibiotics, Vaccines, Diagnostics, Others	Pharmaceuticals	Vaccines
Type	Clinical Mastitis, Sub-Clinical Mastitis	Clinical Mastitis	Sub-Clinical Mastitis
Therapy	Dry Period, Lactating Period	Dry Period	Lactating Period
Route of Administration	Intra-Mammary, Systemic	Intra-Mammary	Intra-Mammary
End-use	Veterinary Hospitals/Clinics, Others	Veterinary Hospitals/Clinics	Veterinary Hospitals/Clinics

Competitive Landscape and Market Positioning

Prominent players in the bovine mastitis market:

1. Zoetis Inc. (United States)

2. Boehringer Ingelheim International GmbH (Germany)

3. Elanco Animal Health Incorporated (United States)

4. Merck & Co. Inc. (United States)

5. Ceva Santé Animale S.A. (France)

6. HIPRA S.A. (Spain)

7. Virbac S.A. (France)

8. ImmuCell Corporation (United States)

9. Forte Healthcare Limited (New Zealand)

10. Dechra Pharmaceuticals PLC (United Kingdom)

The bovine mastitis market is experiencing growing innovation as dairy producers seek effective disease prevention and herd health management solutions. Manufacturers are developing advanced therapeutic formulations, diagnostic technologies, and preventive treatment strategies aimed at reducing infection rates and improving milk quality. Rising awareness regarding livestock productivity and animal health standards is further supporting expansion within the bovine mastitis market.

Industry Development/News

Company Name	Date	Key Development
Biotangents	Nov-24	Biotangents secured £2.3 million in funding led by Eos Advisory, with participation from British Business Investments, Kelvin Capital, and Scottish Enterprise. This capital infusion is earmarked to accelerate the development and commercialization of advanced diagnostic technologies, aiming to improve the detection and clinical management of bovine mastitis within livestock health operations.
Boehringer Ingelheim	Apr-26	Boehringer Ingelheim expanded its livestock health portfolio with the EU-wide launch of LENZELTA®, a mastitis vaccine for dairy cattle. This commercialization effort focuses on preventive immunization to mitigate the incidence and severity of clinical mastitis, providing dairy producers with a strategic tool to enhance herd management and operational health outcomes.
AHV USA	Apr-25	AHV USA established a strategic distribution partnership with Milk Barn to integrate molecular diagnostic technology with real-time dairy monitoring systems. This collaboration seeks to improve the speed and accuracy of early mastitis detection, demonstrating a shift toward technology-enabled management solutions aimed at optimizing herd health and reducing productivity losses in dairy operations.
Zoetis	Aug-23	Zoetis commercialized the Vetscan Mastigram, an on-farm diagnostic test capable of identifying Gram-positive mastitis within eight hours. By enabling rapid testing prior to the subsequent milking cycle in European markets, this product provides a functional innovation that allows for more timely therapeutic interventions and improved decision-making in bovine mastitis management.